financetom
Business
financetom
/
Business
/
Masimo smartwatches infringe Apple design patents, US jury says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Masimo smartwatches infringe Apple design patents, US jury says
Nov 3, 2024 12:04 PM

Oct 25 (Reuters) - Apple ( AAPL ) convinced a federal

jury on Friday that health monitoring tech company Masimo's ( MASI )

smartwatches infringe two of its design patents.

The jury, in Delaware, agreed with Apple ( AAPL ) that Masimo's ( MASI ) W1

and Freedom watches and chargers willfully violated Apple's ( AAPL )

patent rights in smartwatch designs, awarding the tech giant

$250 in damages. Apple's ( AAPL ) attorneys told the court the "ultimate

purpose" of its lawsuit was to win an injunction against sales

of Masimo's ( MASI ) smartwatches after an infringement ruling.

The jury also determined that Masimo's ( MASI ) watches did not

infringe Apple ( AAPL ) patents covering smartwatch inventions that the

tech giant had accused Masimo ( MASI ) of copying.

Masimo ( MASI ) said in a statement that the company appreciated the

jury's verdict "in favor of Masimo ( MASI ) and against Apple ( AAPL ) on nearly

all issues," and that the decision only applied to a

"discontinued module and charger."

"Apple ( AAPL ) primarily sought an injunction against Masimo's ( MASI )

current products, and the jury's verdict is a victory for Masimo ( MASI )

on that issue," Masimo ( MASI ) said.

Apple ( AAPL ) said in a statement that it was "glad the jury's

decision today will protect the innovations we advance on behalf

of our customers."

Irvine, California-based Masimo ( MASI ) accused Apple ( AAPL ) of hiring

away its employees and stealing its pulse oximetry technology

after discussing a potential collaboration. Masimo ( MASI ) convinced the

U.S. International Trade Commission last year to block imports

of Apple's ( AAPL ) Series 9 and Ultra 2 smartwatches after the

commission found that their technology for reading blood oxygen

levels infringed Masimo's ( MASI ) patents.

Apple ( AAPL ) has appealed the decision and resumed selling the

watches after removing the technology. The tech giant

countersued Masimo ( MASI ) for patent infringement in 2022, alleging

that Masimo ( MASI ) copied Apple Watch features to use in its

smartwatches.

Apple ( AAPL ) also accused Masimo ( MASI ) of using lawsuits at the ITC

and in California to "make way for Masimo's ( MASI ) own watch." Masimo ( MASI )

said Apple's ( AAPL ) patent lawsuit was "retaliatory" and "an attempt to

avoid the court in which the parties have been litigating their

dispute."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Israel expects new air defence orders from Europe due to Russia concerns
Israel expects new air defence orders from Europe due to Russia concerns
Jun 15, 2026
* Israel: European demand for Israeli air defence products rises * Official says new contracts are expected within weeks * Defence ministry reports huge interest in Iron Dome system By Sabine Siebold BERLIN, June 15 (Reuters) - Israel expects more orders for air and missile defence systems from European countries soon, with at least one contract expected within weeks, a...
Meta Platforms, Google Among Platforms Targeted by UK's Proposed Under-16 Social Media Ban
Meta Platforms, Google Among Platforms Targeted by UK's Proposed Under-16 Social Media Ban
Jun 15, 2026
05:33 AM EDT, 06/15/2026 (MT Newswires) -- Meta Platforms ( META ) , Alphabet's (GOOG, GOOGL) Google ( GOOG ) and other technology companies could face new restrictions after the UK government said Monday it plans to ban social media platforms from offering services to users under 16. Modeled on Australia's framework, the proposal would cover platforms including Instagram, Facebook,...
Sanofi Says US FDA Approved Tzield for Recently Diagnosed Stage 3 Type 1 Diabetes in Children
Sanofi Says US FDA Approved Tzield for Recently Diagnosed Stage 3 Type 1 Diabetes in Children
Jun 15, 2026
05:19 AM EDT, 06/15/2026 (MT Newswires) -- Sanofi ( SNY ) has received US Food and Drug Administration accelerated approval for Tzield to delay the decline in endogenous insulin production in children aged 8 to 17 years recently diagnosed with stage 3 type 1 diabetes, the company said Friday. The approval was supported by data from a phase 3 study...
Form 8.3
Form 8.3
Jun 15, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Computershare Trustees (Jersey) Limited as trustee of the Schroders Employee Benefit Trust (b) Owner or controller of interests and short positions disclosed,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved